EGFR and non-small cell lung carcinoma: The last 2 decades have witnessed fast evolving treatment landscape of metatastic NSCLC with a biomarker-driven approach, more recently, targeted therapies have been extended to the early-stage setting with approval of several EGFR-tyrosine kinases (TKIs) as adjuvant therapy.